Somatic KRAS mutations have been associated with resistance to EGFR-targeted agents in lung cancer and metastatic CRC [10], and are mutually exclusive with EGFR mutations in large series of NSCLC [4,11]. This evidence concerns the gene KRAS and lung cancer.